Table 3.
Distribution of demographic and tumor characteristics of stages 1–3 first primary invasive breast cancer by race/ethnicity: California Cancer Registry 2000–2010*
| |
Race/Ethnicity |
|||||
|---|---|---|---|---|---|---|
| White | Black | Hispanic | API | Total | ||
|
N (%) |
|
120,435 (67.2%) |
10,637 (5.9%) |
28,380 (15.8%) |
19,691 (11.1%) |
179,143 |
|
Year at diagnosis |
|
|
|
|
|
|
| |
n |
79,226 |
6,662 |
17,054 |
11,641 |
114,583 |
| 2000-2006 |
% within race/ethnicity |
65.8% |
62.6% |
60.1% |
59.1% |
64.0% |
| |
n |
41,209 |
3,975 |
11,326 |
8,050 |
64,560 |
| 2007-2010 |
% within race/ethnicity |
34.2% |
37.4% |
39.9% |
40.9% |
36.0% |
|
Socioeconomic status |
|
|
|
|
|
|
| |
n |
25,016 |
5,454 |
14,848 |
4,550 |
49,868 |
| Lowest/Least Affluent |
% within race/ethnicity |
20.8% |
51.3% |
52.3% |
23.1% |
27.8% |
| |
n |
25,283 |
2,349 |
5,756 |
3,740 |
37,128 |
| Intermediate |
% within race/ethnicity |
21.0% |
22.1% |
20.3% |
19.0% |
20.7% |
| |
n |
70,136 |
2,834 |
7,776 |
11,401 |
92,147 |
| Highest/Most Affluent |
% within race/ethnicity |
58.2% |
26.6% |
27.4% |
57.9% |
51.4% |
|
Age at diagnosis (years) |
|
|
|
|
|
|
| |
n |
1,600 |
299 |
1,215 |
574 |
3,688 |
| <35 |
% within race/ethnicity |
1.3% |
2.8% |
4.3% |
2.9% |
2.1% |
| |
n |
81,900 |
8,055 |
22,331 |
15,784 |
128,070 |
| 35-69 |
% within race/ethnicity |
68.0% |
75.7% |
78.7% |
80.2% |
71.5% |
| |
n |
23,132 |
1,518 |
3,466 |
2,394 |
30,510 |
| 70-79 |
% within race/ethnicity |
19.2% |
14.3% |
12.2% |
12.2% |
17.0% |
| |
n |
12,223 |
672 |
1,190 |
851 |
14,936 |
| 80-89 |
% within race/ethnicity |
10.1% |
6.3% |
4.2% |
4.3% |
8.3% |
| |
n |
1,580 |
93 |
178 |
88 |
1,939 |
| 90+ |
% within race/ethnicity |
1.3% |
0.9% |
0.6% |
0.4% |
1.1% |
|
AJCC stage |
n |
62,693 |
4,195 |
11,321 |
9,326 |
87,535 |
| Stage 1 |
% within race/ethnicity |
52.1% |
39.4% |
39.9% |
47.4% |
48.9% |
| |
n |
45,791 |
4,751 |
12,608 |
8,258 |
71,408 |
| Stage 2 |
% within race/ethnicity |
38.0% |
44.7% |
44.4% |
41.9% |
39.9% |
| |
n |
11,951 |
1,691 |
4,451 |
2,107 |
20,200 |
| Stage 3 |
% within race/ethnicity |
9.9% |
15.9% |
15.7% |
10.7% |
11.3% |
|
ER/PR/HER2 subtype |
|
|
|
|
|
|
| |
n |
52,797 |
3,240 |
10,526 |
7,859 |
74,422 |
| ER+/PR+/HER2- |
% within race/ethnicity |
60.3% |
42.9% |
51.0% |
54.9% |
57.2% |
| |
n |
7,689 |
709 |
2,181 |
1,665 |
12,244 |
| ER+/PR+/HER2+ |
% within race/ethnicity |
8.8% |
9.4% |
10.6% |
11.6% |
9.4% |
| |
n |
8,791 |
735 |
1,816 |
1,172 |
12,514 |
| ER+/PR-/HER2- |
% within race/ethnicity |
10.0% |
9.7% |
8.8% |
8.2% |
9.6% |
| |
n |
2,675 |
252 |
678 |
513 |
4,118 |
| ER+/PR-/HER2+ |
% within race/ethnicity |
3.1% |
3.3% |
3.3% |
3.6% |
3.2% |
| |
n |
640 |
77 |
194 |
113 |
1,024 |
| ER-/PR+/HER2- |
% within race/ethnicity |
0.7% |
1.0% |
0.9% |
0.8% |
0.8% |
| |
n |
281 |
45 |
126 |
61 |
513 |
| ER-/PR+/HER2+ |
% within race/ethnicity |
0.3% |
0.6% |
0.6% |
0.4% |
0.4% |
| |
n |
9,924 |
1,929 |
3,371 |
1,601 |
16,825 |
| ER-/PR-/HER2- |
% within race/ethnicity |
11.3% |
25.5% |
16.3% |
11.2% |
12.9% |
| |
n |
4,789 |
572 |
1,748 |
1,329 |
8,438 |
| ER-/PR-/HER2+ |
% within race/ethnicity |
5.5% |
7.6% |
8.5% |
9.3% |
6.5% |
|
Tumor grade |
n |
29,749 |
1,516 |
4,613 |
3,454 |
39,332 |
| Grade I |
% within race/ethnicity |
26.2% |
15.1% |
17.3% |
18.6% |
23.3% |
| |
n |
49,124 |
3,570 |
10,610 |
7,972 |
71,276 |
| Grade II |
% within race/ethnicity |
43.3% |
35.5% |
39.8% |
43.0% |
42.3% |
| |
n |
32,747 |
4,691 |
10,823 |
6,785 |
55,046 |
| Grade III |
% within race/ethnicity |
28.9% |
46.7% |
40.6% |
36.6% |
32.6% |
| |
n |
1,802 |
276 |
620 |
345 |
3,043 |
| Grade IV | % within race/ethnicity | 1.6% | 2.7% | 2.3% | 1.9% | 1.8% |
*Excludes cases classified as American Indian and Hispanic + Other race.